Clinical Trials

Find a Trial

Trial Results

17 protocol(s) meet the specified criteria
14-13546OPEN TO ACCRUAL
Pathogen Identification in Pediatric Hematopoietic Stem Cell Transplant Patients with Suspected Lower Respiratory Tract Infection
A081105OPEN TO ACCRUAL
RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF ERLOTINIB OR PLACEBO IN PATIENTS WITH COMPLETELY RESECTED EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
A151216OPEN TO ACCRUAL
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
ADP-0000-001OPEN TO ACCRUAL
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Non-Small Cell Lung Cancer (NSCLC)
BAY94-9343OPEN TO ACCRUAL
Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY 94-9343)in Patients with Mesothelin Expressing Advanced or Recurrent Malignancies
BBI608-201OPEN TO ACCRUAL
A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies
BTCRC-LUN16-081OPEN TO ACCRUAL
Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
BTCRCLUN15-029OPEN TO ACCRUAL
A Phase II Trial of Chemotherapy plus Pembrolizumab in patients with advanced NSCLC previously treated with PD-1 or PD-L1 Inhibitor
CTMX-M-2009-001OPEN TO ACCRUAL
A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors
E4512OPEN TO ACCRUAL
A Phase III Double Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
EA5142OPEN TO ACCRUAL
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) ? A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
IUSCC-0580OPEN TO ACCRUAL
Blood Based Recurrence Detection for Patients with Lung Cancer Receiving Radiation Therapy
IUSCC-0602OPEN TO ACCRUAL
Telephone Support Program for Advanced Lung Cancer Patients and their Family Caregivers
IUSCC-0612OPEN TO ACCRUAL
Mindfulness to Enhance Quality of Life and Support Advance Care Planning (MEANING): A Randomized Controlled Pilot Trial for Adults with Metastatic Cancer and Their Family Caregivers
IUSCC-0623OPEN TO ACCRUAL
A retrospective review of clinical, radiographic, radiation-treatment related, and biological factors associated with pneumonitis in patients treated with chemoradiation followed by pembrolizumab: a companion study to HCRN LUN 14-179
IUSCC-0624OPEN TO ACCRUAL
Phase I/II trial evaluating five fraction SABR dose escalation for early stage Squamous Cell Carcinoma of the Lung
NKTR16-214-02OPEN TO ACCRUAL
A PHASE 1/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-214 AND NIVOLUMAB IN PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES